Bristol Net Income From Continuing Ops vs Other Operating Expenses Analysis

BMY Stock  USD 57.88  2.05  3.67%   
Bristol Myers financial indicator trend analysis is way more than just evaluating Bristol Myers Squibb prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bristol Myers Squibb is a good investment. Please check the relationship between Bristol Myers Net Income From Continuing Ops and its Other Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Net Income From Continuing Ops vs Other Operating Expenses

JavaScript chart by amCharts 3.21.1520162018202020222024-8B-6B-4B-2B02B4B6B8B 14B16B18B20B22B24B26B28B30B32B34B36B38B40B
JavaScript chart by amCharts 3.21.15Net Income From Continuing Opstotal: 15.8BOther Operating Expensestotal: 279.1B

Net Income From Continuing Ops vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bristol Myers Squibb Net Income From Continuing Ops account and Other Operating Expenses. At this time, the significance of the direction appears to have weak contrarian relationship.
Net Income From Continuing OpsOther Operating ExpensesDiversified AwayNet Income From Continuing OpsOther Operating ExpensesDiversified Away100%
The correlation between Bristol Myers' Net Income From Continuing Ops and Other Operating Expenses is -0.05. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Bristol Myers Squibb, assuming nothing else is changed. The correlation between historical values of Bristol Myers' Net Income From Continuing Ops and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Bristol Myers Squibb are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Net Income From Continuing Ops i.e., Bristol Myers' Net Income From Continuing Ops and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

-0.05
Relationship DirectionNegative 
Relationship StrengthInsignificant

Net Income From Continuing Ops

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bristol Myers Squibb. It is also known as Bristol Myers overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
At this time, Bristol Myers' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.18 in 2025, whereas Discontinued Operations is likely to drop slightly above 6 B in 2025.
 2022 2023 2024 2025 (projected)
Gross Profit36.0B34.3B36.4B38.2B
Total Revenue46.2B45.0B48.3B50.7B

Bristol Myers fundamental ratios Correlations

0.960.820.910.850.790.95-0.140.91.00.580.770.780.960.480.980.840.160.880.980.70.950.780.950.630.88
0.960.870.940.70.780.99-0.290.910.940.520.750.830.980.490.990.740.190.860.990.810.950.740.870.60.91
0.820.870.970.440.710.89-0.310.70.780.690.510.80.860.440.840.510.380.630.890.860.90.540.610.640.79
0.910.940.970.60.810.94-0.210.80.880.640.620.860.950.420.920.670.290.710.950.890.960.680.740.70.86
0.850.70.440.60.690.660.160.780.870.30.780.560.740.410.770.85-0.060.790.740.330.720.790.930.50.67
0.790.780.710.810.690.760.130.760.770.240.750.880.850.430.770.660.050.540.790.770.820.80.690.860.82
0.950.990.890.940.660.76-0.310.870.930.560.680.820.980.460.980.740.220.840.990.830.930.710.850.580.91
-0.14-0.29-0.31-0.210.160.13-0.31-0.17-0.14-0.26-0.06-0.14-0.14-0.63-0.240.060.02-0.46-0.23-0.22-0.14-0.11-0.130.18-0.35
0.90.910.70.80.780.760.87-0.170.880.290.930.790.890.520.910.680.030.840.90.660.910.790.870.610.83
1.00.940.780.880.870.770.93-0.140.880.580.750.740.950.480.980.850.120.90.970.650.910.770.970.580.86
0.580.520.690.640.30.240.56-0.260.290.580.110.270.50.140.550.50.310.470.580.40.550.130.440.270.46
0.770.750.510.620.780.750.68-0.060.930.750.110.70.740.570.760.63-0.120.720.740.50.780.780.780.680.78
0.780.830.80.860.560.880.82-0.140.790.740.270.70.880.490.780.55-0.070.620.820.910.860.820.640.660.8
0.960.980.860.950.740.850.98-0.140.890.950.50.740.880.420.970.790.160.80.980.850.960.780.860.670.9
0.480.490.440.420.410.430.46-0.630.520.480.140.570.490.420.480.23-0.170.690.470.320.460.650.520.310.64
0.980.990.840.920.770.770.98-0.240.910.980.550.760.780.970.480.790.180.880.990.750.940.740.920.60.9
0.840.740.510.670.850.660.740.060.680.850.50.630.550.790.230.790.040.730.770.490.730.660.850.550.76
0.160.190.380.29-0.060.050.220.020.030.120.31-0.12-0.070.16-0.170.180.04-0.020.210.130.25-0.230.020.250.09
0.880.860.630.710.790.540.84-0.460.840.90.470.720.620.80.690.880.73-0.020.850.490.780.760.930.330.81
0.980.990.890.950.740.790.99-0.230.90.970.580.740.820.980.470.990.770.210.850.790.960.740.890.640.9
0.70.810.860.890.330.770.83-0.220.660.650.40.50.910.850.320.750.490.130.490.790.820.620.490.640.76
0.950.950.90.960.720.820.93-0.140.910.910.550.780.860.960.460.940.730.250.780.960.820.750.820.730.87
0.780.740.540.680.790.80.71-0.110.790.770.130.780.820.780.650.740.66-0.230.760.740.620.750.80.570.79
0.950.870.610.740.930.690.85-0.130.870.970.440.780.640.860.520.920.850.020.930.890.490.820.80.490.81
0.630.60.640.70.50.860.580.180.610.580.270.680.660.670.310.60.550.250.330.640.640.730.570.490.71
0.880.910.790.860.670.820.91-0.350.830.860.460.780.80.90.640.90.760.090.810.90.760.870.790.810.71
Click cells to compare fundamentals

Bristol Myers Account Relationship Matchups

Bristol Myers fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets118.5B109.3B96.8B95.2B92.6B97.2B
Short Long Term Debt Total51.7B45.6B40.7B41.5B51.2B53.8B
Other Current Liab13.2B13.0B13.5B14.4B16.4B17.3B
Total Current Liabilities19.1B21.9B21.9B22.3B23.8B25.0B
Total Stockholder Equity37.8B35.9B31.1B29.4B16.3B15.1B
Property Plant And Equipment Net6.7B7.0B7.5B8.0B7.1B5.3B
Net Debt37.1B31.6B31.6B30B40.9B42.9B
Retained Earnings21.3B23.8B25.5B28.8B14.9B21.9B
Cash14.5B14.0B9.1B11.5B10.3B10.9B
Non Current Assets Total88.3B76.1B69.5B63.4B62.8B66.0B
Non Currrent Assets Other2.1B1.7B1.0B1.8B6.4B6.7B
Cash And Short Term Investments14.5B14.0B9.1B12.3B10.9B5.8B
Net Receivables8.5B12.5B13.9B15.3B10.7B11.3B
Good Will20.5B20.5B21.1B21.2B21.7B22.8B
Common Stock Shares Outstanding2.3B2.2B2.1B2.1B2.0B1.6B
Liabilities And Stockholders Equity118.5B109.3B96.8B95.2B92.6B97.2B
Non Current Liabilities Total61.5B51.4B43.8B43.4B52.4B55.1B
Inventory2.1B2.1B2.3B2.7B2.6B1.9B
Other Current Assets5.6B1.3B1.7B1.6B5.6B5.9B
Other Stockholder Equity18.1B13.1B6.5B1.9B2.4B2.5B
Total Liab80.6B73.3B65.7B65.7B76.2B80.0B
Property Plant And Equipment Gross5.9B11.0B11.6B12.8B13.3B14.0B
Total Current Assets30.2B33.3B27.3B31.8B29.8B31.3B
Accumulated Other Comprehensive Income(1.8B)(1.3B)(1.3B)(1.5B)(1.2B)(1.3B)
Short Term Debt2.5B5.1B4.4B3.3B2.2B1.1B
Intangible Assets53.2B42.8B36.4B27.1B23.3B24.5B
Accounts Payable2.7B2.9B3.0B3.3B3.6B1.9B
Short Term Investments1.3B3.2B130M816M513M487.4M
Other Liab15.9B12.3B11.0B7.4B8.5B4.9B
Other Assets4.8B7.3B3.3B2.9B3.3B3.3B
Long Term Debt48.3B39.6B35.1B36.7B47.6B50.0B
Treasury Stock(26.2B)(31.3B)(38.6B)(43.8B)(39.4B)(37.4B)
Property Plant Equipment6.3B5.9B6.0B6.3B7.2B5.8B
Current Deferred Revenue3.6B3.7B1.3B271M311.7M296.1M
Net Tangible Assets(34.9B)(36.0B)(28.2B)(25.9B)(23.4B)(22.2B)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.